Zobrazeno 1 - 10
of 200
pro vyhledávání: '"E S Vitetta"'
Publikováno v:
The Journal of Immunology. 155:3196-3204
The present studies were designed to further determine whether the CD25 marker could distinguish between cells productively and latently infected with HIV. This was accomplished by combining immunotoxin (IT)-mediated killing of CD25+ cells, highly se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3726a20834a27016fd0cb2f006fe23f3
https://doi.org/10.4049/jimmunol.155.6.3196
https://doi.org/10.4049/jimmunol.155.6.3196
Autor:
E S Vitetta
Publikováno v:
The Journal of Immunology. 153:1407-1420
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8075e3ffc6d07e930cd999f1fd4a9c47
https://doi.org/10.4049/jimmunol.153.4.1407
https://doi.org/10.4049/jimmunol.153.4.1407
Publikováno v:
The Journal of Immunology. 152:2368-2376
We have generated a bispecific anti-CD22/anti-CD3 immunotoxin (IT) and determined whether it would exert both lymphokine-activated killer (LAK) T cell-mediated and ricin A chain (dgA)-mediated toxicity to Daudi tumor cells but not to T cells in vitro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5db70e7af236159806d3999eb739e40
https://doi.org/10.4049/jimmunol.152.5.2368
https://doi.org/10.4049/jimmunol.152.5.2368
Publikováno v:
The Journal of Immunology. 150:5202-5208
T cell activation plays a major role in the ability of the HIV to remain latent or establish a productive infection. The alpha-chain of the IL-2R (CD25, Tac, p55) is expressed on activated but not resting T cells and therefore represents an ideal mar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a2f91502d989499d88aa448b5d11509
https://doi.org/10.4049/jimmunol.150.11.5202
https://doi.org/10.4049/jimmunol.150.11.5202
Publikováno v:
The Journal of Immunology. 144:3637-3642
Over the past decade, immunotoxins (IT) composed of mAb covalently coupled to toxins or their subunits have been developed for the treatment of malignancies and autoimmune diseases. Despite specific binding to target cells, not every mAb makes a ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::701be420407d0fe634aa9e19c17b8efc
https://doi.org/10.4049/jimmunol.144.9.3637
https://doi.org/10.4049/jimmunol.144.9.3637
Publikováno v:
The Journal of Immunology. 144:3288-3295
CD4+ murine T cell clones, TH1 and TH2, can be distinguished by both functional responses and by their patterns of lymphokine secretion. Recently, a mAb, 23G2, which reacts with a subset of CD45 molecules (CD45R), has been reported to bind differenti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07b7e242f466e2c4cfc674514072fb69
https://doi.org/10.4049/jimmunol.144.9.3288
https://doi.org/10.4049/jimmunol.144.9.3288
Autor:
T L Stevens, E S Vitetta
Publikováno v:
The Journal of Immunology. 144:869-874
The ability of Th cells, type 1 (TH1), to activate and induce differentiation of B cells into antibody-secreting cells is controversial because 1) some clones of TH1 cells provide help while others do not, and 2) by using the same TH1 clone, differen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8615300d55ba6cdba83f394152c3b978
https://doi.org/10.4049/jimmunol.144.3.869
https://doi.org/10.4049/jimmunol.144.3.869
Publikováno v:
Neoplasma. 50(4)
Allogeneic hematopoietic stem cell transplantation is the treatment of choice for many hematological malignancies. Its efficacy is limited by graft-versus-host disease (GVHD), the leading cause of post-transplant morbidity and mortality. GVHD is medi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::04e1266d15437129e43ed69e5f49d1dd
https://pubmed.ncbi.nlm.nih.gov/12937844
https://pubmed.ncbi.nlm.nih.gov/12937844
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(2)
A retrospective analysis of 102 patients with relapsed, non-Hodgkin's lymphoma treated with two different ricin A chain-containing immunotoxins (ITs) in five Phase I clinical trials indicates that the dose-limiting toxicity, vascular leak syndrome, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b26d3c287ffbd7941f6a1f491554d472
https://pubmed.ncbi.nlm.nih.gov/11234876
https://pubmed.ncbi.nlm.nih.gov/11234876
Autor:
E S, Vitetta
Publikováno v:
Cancer journal (Sudbury, Mass.). 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bcf6ad9c7a41c4adceac6c8f27056044
https://pubmed.ncbi.nlm.nih.gov/10874491
https://pubmed.ncbi.nlm.nih.gov/10874491